Improvement of clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitor golimumab: Results of a 24-Month prospective observation study (GO-COX Study).

Aim: The hip joint is the most commonly affected non-axial joint in ankylosing spondylitis (AS). Data on the effects of tumor necrosis factor-α inhibitors (TNFi) in AS patients with coxitis are limited. The aim of this study was evaluation of coxitis treated with the TNFi golimumab in real-world settings.